Skip to main content
SpringerLink
Log in

The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

Esophageal neuroendocrine carcinoma (NEC) is a rare malignant tumor. The role of surgery in resectable limited disease of esophageal NEC remains unclear. How to select a specific group of limited disease of esophageal NEC who might benefit from surgery remains to be answered.

Methods

Patients undergoing esophagectomy for resectable limited disease of esophageal NEC in our department from January 2007 to June 2015 were analyzed. TNM staging system was applied to describe those patients, and according to their different long-term prognosis after surgery, those patients were subgrouped into surgery response limited disease (SRLD) group and surgery non-response limited disease (SNRLD) group. Both univariate and multivariate analyses were applied to identify potential prognostic factors.

Results

A total of 72 patients with resectable limited disease of esophageal NEC were identified for analysis. The median survival time of those patients was 21.5 months. There was no significant survival differences among stage I, stage IIA, and stage IIB patients, but all these patients had significantly longer survival than stage III patients. Therefore, stage I, stage IIA, and stage IIB patients were aggregated together as SRLD group, and stage III patients were aggregated as SNRLD group. SRLD patients obtained significantly longer survival than SNRLD patients in both univariate analysis and multivariate analysis. Moreover, adjuvant therapy could significantly benefit SRLD patients (P = 0.004) but could not benefit SNRLD patients (P = 0.136).

Conclusions

Different responses to surgery existed in resectable limited disease of esophageal NEC indicating the need of further subgrouping for those patients. The resectable limited disease of esophageal NEC could be further subgrouped into SRLD group and SNRLD group according to the TNM staging system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–16

    Article  PubMed  Google Scholar 

  2. Rindi G (2011) Wiedenmann B Neuroendocrine neoplasms of the gut and pancreas: new insights Nature reviews. Endocrinology 8:54–64

    PubMed  Google Scholar 

  3. Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72

    Google Scholar 

  4. Huang Q, Wu H, Nie L et al (2013) Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol 37:467–483

    Article  PubMed  Google Scholar 

  5. Nakajima Y, Zenda S, Minashi K et al (2012) Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? Int J Clin Oncol 17:610–615

    Article  PubMed  CAS  Google Scholar 

  6. Diagnosis Stahel RA (1991) staging, and prognostic factors of small cell lung cancer. Curr Opin Oncol 3:306–311

    Article  Google Scholar 

  7. Wang SY, Mao WM, Du XH et al (2013) The 2002 AJCC TNM classification is a better predictor of primary small cell esophageal carcinoma outcome than the VALSG staging system. Chin J Cancer 32:342–352

    PubMed  PubMed Central  Google Scholar 

  8. Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer–what limits limited disease? Lung Cancer (Amsterdam, Netherlands) 37:271–276

    Article  Google Scholar 

  9. Situ D, Lin Y, Long H et al (2013) Surgical treatment for limited-stage primary small cell cancer of the esophagus. Ann Thorac Surg 95:1057–1062

    Google Scholar 

  10. Hou X, Wei JC, Wu JX et al (2013) Multidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinoma. PloS One 8:e69259

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119

    Google Scholar 

  12. Meng MB, Zaorsky NG, Jiang C et al (2013) Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiother Oncol 106:317–322

    Google Scholar 

  13. Chen WW, Wang F, Chen S et al (2014) Detailed analysis of prognostic factors in primary esophageal small cell carcinoma. Ann Thorac Surg 97:1975–1981

    Google Scholar 

  14. Jatoi A, Miller RC (2008) Should we recommend surgery to patients with limited small cell carcinoma of the esophagus? J Thorac Oncol 3:1373–1376

    Article  PubMed  Google Scholar 

  15. Maru DM, Khurana H, Rashid A et al (2008) Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 32:1404–1411

    Google Scholar 

  16. Tanaka T, Matono S, Nagano T et al (2010) Surgical management for small cell carcinoma of the esophagus. Dis Esophagus 23:502–505

    Article  PubMed  CAS  Google Scholar 

  17. Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119

    Article  PubMed  Google Scholar 

  18. Yau KK, Siu WT, Wong DC et al (2007) Non-operative management of small cell carcinoma of esophagus. Dis Esophagus 20:487–490

    Article  PubMed  CAS  Google Scholar 

  19. Lu XJ, Luo JD, Ling Y et al (2013) Management of small cell carcinoma of esophagus in China. J Gastrointest Surg 17:1181–1187

    Google Scholar 

  20. Deng HY, Ni PZ, Wang YC et al (2016) Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis 8:1250–1256

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lv J, Liang J, Wang J et al (2008) Primary small cell carcinoma of the esophagus. J Thorac Oncol 3:1460–1465

    Google Scholar 

  22. de Hoyos A, DeCamp MM (2014) Surgery for small cell lung cancer. Thorac Surg Clin 24:399–409

    Google Scholar 

  23. Hudson E, Powell J, Mukherjee S et al (2007) Small cell oesophageal carcinoma: an institutional experience and review of the literature. Br J Cancer 96:708–711

    Google Scholar 

  24. Zou B, Li T, Zhou Q et al (2016) Adjuvant therapeutic modalities in primary small cell carcinoma of esophagus patients: a retrospective cohort study of multicenter clinical outcomes. Medicine 95:e3507

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

This work was supported by National Natural Science Foundation of China [Nos. 81672291; 31071210] (to Yi-Dan Lin).

Author information

Author notes

  1. Han-Yu Deng, Gang Li and Jun Luo contributed equally to this study.

Authors and Affiliations

  1. Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, China

    Han-Yu Deng, Gang Li, Jun Luo, Xin-Rui Li, Guha Alai & Yi-Dan Lin

  2. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China

    Han-Yu Deng

Authors
  1. Han-Yu Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin-Rui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guha Alai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi-Dan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi-Dan Lin.

Ethics declarations

Conflict of interests

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deng, HY., Li, G., Luo, J. et al. The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma. World J Surg 42, 2428–2436 (2018). https://doi.org/10.1007/s00268-018-4475-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-018-4475-3

Search

Navigation